Crescent Biopharma, Inc. (CBIO)
NASDAQ · Healthcare
Crescent Biopharma, Inc. Operating Income 2012–2025
Crescent Biopharma, Inc. annual/quarterly operating income history and growth rate from 2012 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Crescent Biopharma, Inc. operating income for the quarter ending March 31, 2026 was -24.7 M, a 73.85% increase year-over-year.
- Crescent Biopharma, Inc. operating income for the twelve months ending March 31, 2026 was -69.6 M, a 37.85% increase year-over-year.
- Crescent Biopharma, Inc. annual operating income for 2025 was -152.6 M, a 288.62% increase from 2023.
- Crescent Biopharma, Inc. annual operating income for 2023 was -39.3 M, a 17.15% decrease from 2022.
- Crescent Biopharma, Inc. annual operating income for 2022 was -47.4 M, a 25.29% decrease from 2021.
- Crescent Biopharma, Inc. annual operating income for 2021 was -63.4 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Crescent Biopharma, Inc. Operating Income — FAQ
Crescent Biopharma, Inc. (CBIO) operating income over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
What is Crescent Biopharma, Inc.'s operating income?
Crescent Biopharma, Inc. (CBIO) reported operating income of -$153M for fiscal 2025.
Where can I see CBIO's operating income history?
The chart and table above show Crescent Biopharma, Inc.'s operating income by year and by quarter, including the growth rate.